港股异动 | 药捷安康-B(02617)涨超10%再破顶 CCA药物市场增长较快公司在细分行业研发领先

智通财经2025-06-30

智通财经APP获悉，药捷安康-B(02617)午后涨超10%，高见30.7港元再创新高，较招股价13.15港元已涨超130%。截至发稿，涨8.83%，报30.2港元，成交额2418.12万港元，总市值一度突破120亿港元。消息面上，药捷安康宣布，其自主研发的多靶点激酶抑制剂替恩戈替尼(TT-00420)，已获美国食品药物管理局(FDA)授予治疗转移性去势抵抗性前列腺癌的快速通道认证。公司表示，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2547543410?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-06-30 14:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2547543410","market":"fut","top_or_hot":-1,"title":"港股异动 | 药捷安康-B(02617)涨超10%再破顶 CCA药物市场增长较快 公司在细分行业研发领先","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，药捷安康-B(02617)午后涨超10%，高见30.7港元再创新高，较招股价13.15港元已涨超130%。截至发稿，涨8.83%，报30.2港元，成交额2418.12万港元，总市值一度突破120亿港元。消息面上，药捷安康宣布，其自主研发的多靶点激酶抑制剂替恩戈替尼(TT-00420)，已获美国食品药物管理局(FDA)授予治疗转移性去势抵抗性前列腺癌的快速通道认证。公司表示，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1311644.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 药捷安康-B(02617)涨超10%再破顶 CCA药物市场增长较快 公司在细分行业研发领先</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 药捷安康-B(02617)涨超10%再破顶 CCA药物市场增长较快 公司在细分行业研发领先\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-06-30 14:41 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1311644.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，药捷安康-B(02617)午后涨超10%，高见30.7港元再创新高，较招股价13.15港元已涨超130%。截至发稿，涨8.83%，报30.2港元，成交额2418.12万港元，总市值一度突破120亿港元。消息面上，药捷安康宣布，其自主研发的多靶点激酶抑制剂替恩戈替尼(TT-00420)，已获美国食品药物管理局(FDA)授予治疗转移性去势抵抗性前列腺癌的快速通道认证。公司表示，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1311644.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CCA","symbol_name":"MFS California Municipal Fund","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1311644.html","article_id":"2547543410","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2547543410","pubTimestamp":1751265711,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"消息面上，药捷安康宣布，其自主研发的多靶点激酶抑制剂替恩戈替尼，已获美国食品药物管理局授予治疗转移性去势抵抗性前列腺癌的快速通道认证。公司在细分行业研发领先，Tinengotinib是全球首个且唯一进入注册临床阶段用于治疗复发或难治性胆管癌患者的FGFR抑制剂。它也是全球首个可能同时抑制FGFR/JAK通路并针对转移性去势抵抗性前列腺癌具有临床疗效证据的研究药物。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"CCA":"MFS California Municipal Fund","BK1161":"生物科技","02617":"药捷安康-B"},"translate_title":"Hong Kong stock market abnormal drug Jieankang-B (02617) rose more than 10% and broke through the top again. The CCA drug market is growing rapidly. The company leads research and development in sub-industries","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02617":1,"CCA":1},"content_text":"智通财经APP获悉，药捷安康-B(02617)午后涨超10%，高见30.7港元再创新高，较招股价13.15港元已涨超130%。截至发稿，涨8.83%，报30.2港元，成交额2418.12万港元，总市值一度突破120亿港元。消息面上，药捷安康宣布，其自主研发的多靶点激酶抑制剂替恩戈替尼(TT-00420)，已获美国食品药物管理局(FDA)授予治疗转移性去势抵抗性前列腺癌的快速通道认证。公司表示，替恩戈替尼目前处于全球三期注册实验的多靶点激酶抑制剂，靶向FGFR/VEGFR、JAK和Aurora激酶发挥抗肿瘤作用，目前正在美国与中国进行的临床试验显示，其在多种实体瘤治疗中具有疗效潜力。国元国际指出，根据弗若斯特沙利文的资料，全球CCA药物市场规模于2024年达到20亿美元，2019年至2024年的年复合增长率为16.2%，预计将于2027年增长至32亿美元，2024年至2027年的年复合增长率为17.1%，并于2030年进一步增至46亿美元，2027年至2030年的年复合增长率为12.8%。公司在细分行业研发领先，Tinengotinib是全球首个且唯一进入注册临床阶段用于治疗复发或难治性胆管癌患者的FGFR抑制剂。它也是全球首个可能同时抑制FGFR/JAK通路并针对转移性去势抵抗性前列腺癌具有临床疗效证据的研究药物。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2547543410","isCrawlerRequest":true}

港股异动 | 药捷安康-B(02617)涨超10%再破顶 CCA药物市场增长较快 公司在细分行业研发领先

精彩评论

港股异动 | 药捷安康-B(02617)涨超10%再破顶 CCA药物市场增长较快公司在细分行业研发领先